Efficient sequence of therapy for advanced and metastatic endometrial cancer
Historical standard of the first line endometrial cancer therapy was combination of paclitaxel and carboplatin. In more than a half of patients with advanced endometrial cancer receiving this combination, disease progression is observed after 2 years. Use of paclitaxel + carboplatin combination in a...
Saved in:
Main Author: | A. A. Rumyantsev (Author) |
---|---|
Format: | Book |
Published: |
ABV-press,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combination of pembrolizumab and lenvatinib in second-line therapy for MSS/pMMR advanced endometrial cancer: literature review and a case report
by: A. D. Darenskaya, et al.
Published: (2024) -
Endometrial cancer at recurrence: To re-sequence or not to re-sequence
by: Katherine Fuh, et al.
Published: (2024) -
Tumor microenvironment parameters as a predictor of the duration of clinical effectiveness of immunotargeted therapy in advanced or metastatic endometrial cancer: A pilot multicenter observational study
by: A. A. Maltseva, et al.
Published: (2024) -
Utility of next generation sequencing to unequivocally establish clonality in synchronous vs metastatic endometrial and ovarian carcinomas
by: Michelle Greenman, et al.
Published: (2024) -
Successful anti-PD-1 therapy in metastatic endometrial cancer with microsatellite instability: a case report
by: T. T. Andabekov, et al.
Published: (2019)